Non-injectable Insulin Market Analysis 2025–2029: Growth Forecast and Competitive Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the non-injectable insulin market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Non-injectable Insulin Market Be Worth By 2029, And What CAGR Will It Achieve?

The non-injectable insulin market has observed rapid expansion in recent years. It is projected to increase from $1.92 billion in 2024 to $2.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to factors such as improved patient compliance, the mitigation of needle phobia, enhanced quality of life, simplified administration, and stable blood glucose control.

The non-injectable insulin market size is projected to undergo significant expansion in the upcoming years. It is foreseen to reach $3.11 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.8%. This growth over the forecast period stems from factors such as sustained focus on patient compliance, ongoing resolutions for needle phobia, continuous improvements in quality of life, persistent enhancements in safety, and a decrease in infection and injury risks. Prominent trends anticipated within this period encompass technological breakthroughs, the progression of technological solutions, the incorporation of digital health, practical uses of nanotechnology, and the development of combination therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which Factors Are Driving The Non-injectable Insulin Market Forward?

The growing challenges of obesity and diabetes are anticipated to drive the expansion of the non-injectable insulin market. Obesity is defined by an excessive accumulation of body fat, typically resulting from an imbalance between energy intake and expenditure, while diabetes mellitus encompasses a group of metabolic disorders characterized by persistently high blood sugar levels. Non-injectable insulin offers a treatment for both conditions, aiming to enhance management by overcoming barriers to conventional insulin therapy, providing potential benefits for weight control, and offering more convenient treatment choices. For instance, the World Heart Federation, a Switzerland-based non-governmental organization, stated in 2022 that global obesity rates were expected to rise, with an estimated 2.3 billion people in 2021, including children and adults, affected by overweight and obesity, a figure projected to increase to 2.7 billion by 2025. Additionally, in April 2023, a report from the British Diabetic Association, a UK-based diabetes charity, revealed that 4.3 million individuals in the UK have diabetes, and more than 2.4 million people are at high risk of developing type 2 diabetes. The registration figures for 2021-22 showed an increase of 148,951 compared to the previous year. Consequently, the increasing prevalence of obesity and diabetes issues is fueling the growth of the non-injectable insulin market.

Which Segments Form The Key Structure Of The Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

What Strategic Shifts And Innovations Are Influencing The Non-injectable Insulin Market?

Leading companies in the non-injectable insulin market are concentrating on groundbreaking advancements in drug delivery systems, such as needle-free oral insulin spray, to enhance the well-being of individuals who manage their diabetes with multiple daily insulin injections. A needle-free insulin spray offers a painless and non-invasive method for regulating blood glucose, providing an easy option as doses can be directly administered into the mouth. For instance, in November 2023, NiedlFree Technologies, an India-based technology platform, unveiled Ozulin, an oral insulin spray. This oral insulin spray is designed to provide a more user-friendly solution for people with diabetes, particularly those who find traditional injectable insulin methods challenging. If approved, Ozulin could significantly change diabetes care by offering a more convenient and pain-free alternative to current insulin injections.

Which Firms Are Making The Biggest Impact In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Is Expected To Lead The Non-injectable Insulin Market In The Next Few Years?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2025, By The Business Research Company

Insulin Pens Syringes Pumps And Injectors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

Insulin Patch Pumps Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Insulin Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795